Eli Lilly Alzheimer's treatment solanezumab failed to slow disease progression
Publishing timestamp: 2023-03-08 23:48:16
Summary
Eli Lilly has announced that it will stop development of its Alzheimer's treatment candidate solanezumab after it failed to slow disease progression in clinical trials. The drug did not clear or halt the accumulation of brain plaque and did not slow cognitive decline in participants who received treatment. Lilly is developing two other Alzheimer's treatments, donanemab and remternetug, which are in late-stage clinical trials. The company plans to publish clinical trial data on donanemab in the second quarter of this year and hopes to receive FDA approval if the data is positive.
Sentiment: NEGATIVE
Tickers: LLY,
Keywords: pandemics, u.s. economy, epidemics, disease outbreaks, business news, business, health care industry, breaking news: business, biotech and pharmaceuticals, biotechnology, eli lilly and co, politics,